ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CID-103

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Purpura · Multiple Myeloma, led by CASI Pharmaceuticals.

Drug pageCID-103: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jun 4, 20254 company-led studies, 3 open or runningNext primary completion: Nov 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CASI Pharmaceuticals43 open or runningphase 2since Jun 4, 2025Feb 8, 2021Nov 30, 2028phase 2 · NCT07946549

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 8, 2021First study: phase 1 study in Multiple MyelomaFirst studyNCT04758767 · 10 enrolled · France, United Kingdom
  2. Jun 4, 2025Phase 2 study in PurpuraNCT07017725 · 75 planned · China
  3. May 20, 2026Phase 2 study in Antibody Mediated RejectionNCT07641426 · 58 planned · China
  4. Nov 12, 2026Phase 2 study in Chronic Immune ThrombocytopeniaNCT07946549 · 54 planned · China

Ahead

  1. Nov 30, 2028Primary completion: phase 2 study in Chronic Immune ThrombocytopeniaNCT07946549
  2. May 2030Primary completion: phase 2 study in Antibody Mediated RejectionNCT07641426

TargetBeta

CD38 →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), ”NCIt, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07946549Chronic Immune Thrombocytopenia · China2Not yet recruitingNov 30, 202854
NCT07641426Antibody Mediated Rejection · China2RecruitingMay 203058
NCT07017725Purpura · China2RecruitingJun 1, 202675
NCT04758767Multiple Myeloma · France, United Kingdom1CompletedJan 19, 202310

How it is read

Names in the registry

  • “CID-103”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.